ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 580

Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry

Stanley Cohen1, Heather J Litman2, Connie Chen3, Tatjana Lukic3, Ann Madsen3, Liza Takiya4, Kimberly J Dandreo2, Taylor Blachley2 and Jeffrey Greenberg2, 1Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2Corrona LLC, Waltham, MA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Collegeville, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Comparative effectiveness and harms, registry, rheumatoid arthritis (RA) and tofacitinib

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Session Title: Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release (XR) dose of tofacitinib 11 mg once daily (QD) was approved. Limited clinical or real-world data exist comparing efficacy outcomes between 11 mg QD and 5 mg BID doses. We aimed to compare the efficacy of these formulations.

Methods: Treatment effectiveness at 6 (±3) months (mos) after initiation (baseline) was evaluated in an observational cohort of patients (pts) initiating tofacitinib 5 mg BID or 11 mg QD between February 2016 and March 2018, identified from the Corrona US RA Registry. The primary outcome was achievement of a minimum clinically important difference (MCID) in Clinical Disease Activity Index (CDAI) improvement at approximately the 6-mo visit following initiation. The MCID was dependent on baseline disease activity (≥2 if low baseline CDAI [≤10], ≥6 if moderate baseline CDAI [10<CDAI≤22], and ≥11 if high baseline CDAI [>22]). Secondary outcomes included: CDAI change from baseline to 6-mo visit, Pt Pain, and Pt Fatigue; achievement of low disease activity (LDA; CDAI ≤10) in pts without baseline LDA, or remission (CDAI ≤2.8) in pts without baseline remission, at 6 mos; and improvement ≥MCID in HAQ (≥0.22) at 6 mos. Outcomes were compared between groups in unadjusted analyses and adjusted linear and logistic regression models (covariates: age, sex, baseline CDAI, duration of RA [a priori decision], and additional covariates with standardized differences >0.2). An exploratory analysis (limited sample size) was conducted to examine 6-mo outcomes in pts who switched to 11 mg QD after 5 mg BID initiation.

Results: 791 pts initiated tofacitinib (11 mg QD: n=460; 5 mg BID: n=234), of whom 334 pts (11 mg QD: n=196; 5 mg BID: n=138) had a registry visit and thus CDAI data at 6 mos after initiation. Baseline characteristics are shown in the Table. There were no significant differences in the proportion of pts with CDAI improvements ≥MCID between formulations with and without adjustment (23.5% vs 21.0%; odds ratio 1.23; 95% confidence interval 0.70, 2.15; covariates added in the model were prior number of non-TNF inhibitors and biologic DMARDs). There were no significant differences in the odds of achieving LDA, remission or improvement in HAQ ≥0.22 between formulations with adjustment (Table). Similar proportions of pts initiating 11 mg QD and 5 mg BID remained on tofacitinib at 6 mos (61.2% vs 67.4%; p=0.43). There were 135 switchers (5 mg BID to 11 mg QD); their post-6-mo outcomes were similar to those at the time of switch.

Conclusion: Results suggest that pts with RA who initiated treatment with tofacitinib 11 mg QD achieved comparable efficacy outcomes with pts who initiated with 5 mg BID. Although currently available person years of exposure is limited, data do not suggest the emergence of any new or unexpected safety risks for the XR formulation.


Disclosure: S. Cohen, Pfizer Inc, 2,Pfizer Inc, 5; H. J. Litman, Corrona, LLC, 3; C. Chen, Pfizer Inc, 1,Pfizer Inc, 3; T. Lukic, Pfizer Inc, 1,Pfizer Inc, 3; A. Madsen, Pfizer Inc, 1,Pizer Inc, 3; L. Takiya, Pfizer Inc, 1,Pfizer Inc, 3; K. J. Dandreo, Corrona, LLC, 3; T. Blachley, Corrona, LLC, 3; J. Greenberg, Corrona, LLC, 1,Corrona, LLC, 3,Eli Lilly, Genentech, Janssen, Pfizer Inc, 5.

To cite this abstract in AMA style:

Cohen S, Litman HJ, Chen C, Lukic T, Madsen A, Takiya L, Dandreo KJ, Blachley T, Greenberg J. Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/clinical-effectiveness-of-tofacitinib-11mg-once-daily-qd-versus-tofacitinib-5mg-twice-daily-bid-in-the-corrona-us-ra-registry/. Accessed August 12, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-effectiveness-of-tofacitinib-11mg-once-daily-qd-versus-tofacitinib-5mg-twice-daily-bid-in-the-corrona-us-ra-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies